Drug Profile
Dordaviprone - Chimerix
Alternative Names: NSC-350625; ONC 201; OP-10; TIC-10; TRAIL-inducing compound 10Latest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Oncoceutics
- Developer Brown University; Case Comprehensive Cancer Center; Chimerix; Fox Chase Cancer Center; Kazia Therapeutics; Ohara Pharmaceutical; Oncoceutics; Rutgers; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
- Class 3-ring heterocyclic compounds; Antineoplastics; Imidazoles; Pyridines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Endopeptidase Clp stimulants; TNF-related apoptosis-inducing ligand receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Glioma
- Phase II Breast cancer; Endometrial cancer; Glioblastoma; Neuroendocrine tumours
- Phase I/II Acute myeloid leukaemia; Colorectal cancer; Gallbladder cancer; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I Cancer; Renal failure
- Preclinical Adenocarcinoma; Liver cancer; Ovarian cancer; Prostate cancer; Sarcoma; Small cell lung cancer; Thyroid cancer
- No development reported Mantle-cell lymphoma; Pancreatic cancer; Solid tumours
Most Recent Events
- 16 Jan 2024 Fox Chase Cancer Center and Oncoceutics terminated a phase II trial for Endometrial cancer (Metastatic disease, Recurrent, Second-line therapy or greater) (PO)(NCT03099499)
- 06 Nov 2023 Chimerix completes a phase I pharmacokinetic trial in Cancer (In volunteers, In adults) in New Zealand (PO, Capsule) (ACTRN12621001003864)
- 10 Sep 2023 Drug-drug interactions and adverse events data from a phase I trial in healthy volunteers presented at the American College of Clinical Pharmacology Annual Meeting (AACP-2023)